ID   WM239A
AC   CVCL_6795
SY   WM-239A; WM-239-A; WM 239-A; WM 239A; WM-239; WM239; WM 239; WC00044
DR   BTO; BTO_0003474
DR   cancercelllines; CVCL_6795
DR   Cell_Model_Passport; SIDM00978
DR   Coriell; WC00044
DR   Cosmic; 888850
DR   Cosmic; 928690
DR   Cosmic; 972260
DR   Cosmic; 1155288
DR   Cosmic; 1155564
DR   Cosmic; 1303069
DR   Cosmic; 1477413
DR   GDSC; 1240225
DR   GEO; GSM109034
DR   GEO; GSM188232
DR   GEO; GSM188262
DR   GEO; GSM188321
DR   IARC_TP53; 24993
DR   PharmacoDB; WM239A_1670_2019
DR   Progenetix; CVCL_6795
DR   Rockland; WM239A-01-0001
DR   Wikidata; Q54994215
RX   PubMed=2253310;
RX   PubMed=3020539;
RX   PubMed=3856042;
RX   PubMed=4053039;
RX   PubMed=15009714;
RX   PubMed=16827748;
RX   PubMed=18632627;
WW   Info; Wistar; -; https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Hemizygous (Wistar).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (PubMed=15009714; Wistar).
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Transcriptomics; Microarray.
CC   Discontinued: Coriell; WC00044; probable.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): Wistar
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D21S11: 28,29
ST   D5S818: 12,13
ST   D7S820: 7,8
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0040 ! WM115
OI   CVCL_L033 ! WM165-1
OI   CVCL_RN55 ! WM165-2
OI   CVCL_RN56 ! WM239B
OI   CVCL_RN57 ! WM266-1
OI   CVCL_RN58 ! WM266-2
OI   CVCL_RN59 ! WM266-3
OI   CVCL_2765 ! WM266-4
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 30
CH   CVCL_VS31 ! WM239A HmR
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn, Meenhard
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235; PMCID=PMC2615688;
RA   Smalley, Keiran S.M.
RA   Contractor, Rooha
RA   Nguyen, Thiennga K.
RA   Xiao, Min
RA   Edwards, Robin
RA   Muthusamy, Viswanathan
RA   King, Alastair J.
RA   Flaherty, Keith Thomas
RA   Bosenberg, Marcus W.
RA   Herlyn, Meenhard
RA   Nathanson, Katherine L.
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek, Keith S.
RA   Schlegel, Natalie C.
RA   Brafford, Patricia
RA   Sucker, Antje
RA   Ugurel, Selma
RA   Kumar, Rajiv
RA   Weber, Barbara L.
RA   Nathanson, Katherine L.
RA   Phillips, Donald J.
RA   Herlyn, Meenhard
RA   Schadendorf, Dirk
RA   Dummer, Reinhard
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=3856042; DOI=10.1093/jnci/74.2.283;
RA   Herlyn, Meenhard
RA   Balaban-Malenbaum, Gloria Brady
RA   Bennicelli, Jeannette L.
RA   Guerry, DuPont 4th
RA   Halaban, Ruth
RA   Herlyn, Dorothee
RA   Elder, David E.
RA   Maul, Gerd G.
RA   Steplewski, Zenon
RA   Nowell, Peter Carey
RA   Clark, Wallace H. Jr.
RA   Koprowski, Hilary
RT   "Primary melanoma cells of the vertical growth phase: similarities to
RT   metastatic cells.";
RL   J. Natl. Cancer Inst. 74:283-289(1985).
//
RX   PubMed=4053039;
RA   Herlyn, Meenhard
RA   Thurin, Jan
RA   Balaban-Malenbaum, Gloria Brady
RA   Bennicelli, Jeannette L.
RA   Herlyn, Dorothee
RA   Elder, David E.
RA   Bondi, Edward
RA   Guerry, DuPont 4th
RA   Nowell, Peter Carey
RA   Clark, Wallace H. Jr.
RA   Koprowski, Hilary
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x; PMCID=PMC2586668;
RA   Tsao, Hensin
RA   Goel, Vikas
RA   Wu, Heng
RA   Yang, Guang
RA   Haluska, Frank G.
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
//
RX   PubMed=3020539; DOI=10.1073/pnas.83.19.7197; PMCID=PMC386682;
RA   Westermark, Bengt
RA   Johnsson, Anders
RA   Paulsson, Ylva
RA   Betsholtz, Christer
RA   Heldin, Carl-Henrik
RA   Herlyn, Meenhard
RA   Rodeck, Ulrich
RA   Koprowski, Hilary
RT   "Human melanoma cell lines of primary and metastatic origin express
RT   the genes encoding the chains of platelet-derived growth factor (PDGF)
RT   and produce a PDGF-like growth factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7197-7200(1986).
//